Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Post by Ingiboyon Aug 30, 2024 4:00am
368 Views
Post# 36202349

Special Independent Committee

Special Independent CommitteeFrom the N/R yesterday:
"Following the negotiation and recommendation of a special independent committee of RepliCel Life Sciences Inc.'s board of directors......"


"the special committee is unanimous in its belief that the transaction is in the best interests of the company and its shareholders," said David Hall, chair of the special committee."

The use the word "independent"  is a bit of a oxymoron here.  How independent can this committee be if it is made up of the Directors of the company.  Also we have no idea if any of the members have any connection to this new numbered company of Andrew Schutte.
I will say it again, this is the biggest boondoggle in the history of takeovers.  He is offering to simply take over the company and give the minority shareholders an 8% Royalty or quasi Dividend if and when there is any profit after expenses of this new numbered company.  Wow, how generous is that.  If the assets of Replicel are sold the shareholders of which he is one get 75% of the residuals. Why as a the existing CEO of the company is he not actively trying to sell the company and 100% of the residuals go to the shareholders and forget about this silly takeover.


<< Previous
Bullboard Posts
Next >>